Despite the broad potential of RMP’s, clinical translation has been uneven. Barriers to broader adoption include regulatory uncertainty, paucity of clinically relevant data, the dynamic nature of modern cell science, less than-ethical “stem cell” marketing, non-standardized protocols, uncertain revenue models, and inadequate education and training of healthcare professionals and patients alike. As with many major advances in medicine – hematology, IVF, orthopedic surgery to name but a few – broad adoption of RMP’s will require clinical/ scientific leadership, protocol standardization, professional and patient education, and regulatory and third party payor acceptance. Regen Med — comprising internationally recognized clinical and thought leaders in regenerative medicine — is dedicated to assisting hospitals as well as smaller medical practices address these issues. Being product agnostic, Regen Med is able to align its interests with its “Affiliates” in establishing approaches to regenerative medicine which are evidence based, regulatorily-compliant and economically sensible.
To read more, please download our full brochure: HCTCenter_Brochure_DIGITALLeave a reply →